Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ProtoGene was a pioneering genomics technology company that developed high-throughput DNA synthesis and microarray production systems. The company's core innovation was a proprietary ink-jet printing technology used to synthesize oligonucleotides directly on surfaces, enabling the creation of custom DNA microarrays for genetic analysis. This technology significantly reduced the cost and time required for large-scale genomic studies compared to traditional photolithographic methods. In 2001, ProtoGene was acquired by Agilent Technologies for approximately $210 million, where its technology became a foundational component of Agilent's genomics business unit.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ProtoGene.